ArticleFrontiers in immunology2022

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.

Niklas Baumann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.